human
coronavirus
caus
upper
lower
respiratori
tract
infect
human
sixth
human
coronaviru
hcov
isol
patient
present
sever
respiratori
ill
man
die
result
renal
respiratori
failur
admiss
hospit
jeddah
saudi
arabia
aetiolog
agent
eventu
identifi
coronaviru
design
middl
east
respiratori
syndrom
coronaviru
merscov
merscov
report
countri
across
middl
east
europ
north
africa
asia
juli
merscov
laboratori
confirm
case
result
death
report
global
major
case
arabian
peninsula
review
summaris
current
understand
merscov
special
refer
genom
structur
ii
clinic
featur
iii
diagnosi
infect
iv
treatment
vaccin
develop
given
divers
anim
coronavirus
surpris
anoth
human
coronaviru
isol
patient
present
sever
respiratori
ill
june
yearold
man
die
result
renal
respiratori
failur
day
admiss
hospit
jeddah
saudi
arabia
novel
etiolog
agent
subsequ
name
middl
east
respiratori
syndrom
coronaviru
merscov
merscov
one
six
known
human
coronavirus
caus
respiratori
diseas
human
mortal
rate
first
highli
pathogen
human
coronaviru
emerg
sinc
global
scare
caus
sever
acut
respiratori
syndrom
coronaviru
sarscov
kingdom
saudi
arabia
focal
point
ongo
merscov
outbreak
larg
number
religi
pilgrim
congreg
annual
saudi
arabia
drastic
increas
potenti
uncontrol
global
spread
merscov
infect
fact
infect
alreadi
report
countri
across
middl
east
europ
north
africa
asia
review
focuss
current
inform
merscov
special
refer
genom
structur
clinic
featur
diagnosi
infect
treatment
vaccin
develop
also
look
futur
prospect
merscov
spread
prevent
merscov
lineag
c
betacoronaviru
positivesens
singlestrand
rna
ssrna
genom
size
phylogenet
analysi
merscov
done
fulllength
genom
multipl
concaten
genom
fragment
includ
merscov
lineag
c
betacoronaviru
positivesens
singlestrand
rna
ssrna
genom
size
phylogenet
analysi
merscov
done
fulllength
genom
multipl
concaten
genom
fragment
includ
human
dromedari
camel
merscov
genom
share
sequenc
ident
indic
low
mutat
rate
low
varianc
among
genom
merscov
genom
roughli
divid
two
clade
clade
contain
strain
clade
b
strain
belong
cov
genom
first
twothird
merscov
genom
consist
replicas
complex
remain
onethird
encod
structur
protein
spike
envelop
e
membran
nucleocapsid
n
well
five
accessori
protein
requir
genom
replic
figur
like
involv
pathogenesi
flank
region
genom
contain
untransl
region
utr
typic
coronavirus
merscov
accessori
protein
share
homolog
known
host
viru
protein
close
relat
lineag
c
merscov
structur
accessori
proteincod
plasmid
transient
transfect
cell
show
localis
mostli
nucleu
protein
e
n
localis
cytoplasm
furthermor
studi
merscov
deletionmut
orf
attenu
replic
human
airwayderiv
cell
deletionmut
orf
attenu
replic
hepat
carcinomaderiv
cell
clearli
point
import
put
role
merscov
accessori
protein
viral
replic
least
vitro
set
princip
respons
mammalian
cell
viral
infect
activ
type
interferon
ifn
mediat
innat
immun
respons
product
type
ifn
hand
evas
host
innat
immun
ifn
antagon
critic
figur
schemat
organ
human
coronaviru
cov
genom
hcov
genom
kb
kb
size
end
overlap
read
frame
blue
make
twothird
genom
remain
one
third
genom
expand
region
encod
structur
white
accessori
protein
grey
merscov
structur
accessori
proteincod
plasmid
transient
transfect
cell
show
localis
mostli
nucleu
protein
e
n
localis
cytoplasm
furthermor
studi
merscov
deletionmut
orf
attenu
replic
human
airwayderiv
cell
deletionmut
orf
attenu
replic
hepat
carcinomaderiv
cell
clearli
point
import
put
role
merscov
accessori
protein
viral
replic
least
vitro
set
princip
respons
mammalian
cell
viral
infect
activ
type
interferon
ifn
mediat
innat
immun
respons
product
type
ifn
hand
evas
host
innat
immun
ifn
antagon
critic
compon
viral
pathogenesi
mediat
virusencod
ifn
antagonist
protein
protein
block
one
key
signal
protein
ifn
pathway
enhanc
viral
replic
pathogenesi
coronavirus
similarli
evolv
mechan
imped
bypass
innat
immun
host
variou
level
ultim
contribut
coronaviru
virul
variou
coronaviru
protein
previous
implic
disrupt
signal
transduct
event
requir
ifn
respons
often
interf
host
type
interferon
induct
evid
merscov
induc
type
ifn
weakli
late
infect
suggest
merscov
also
evolv
mechan
evad
host
immun
system
fact
merscov
protein
report
strong
ifn
antagonist
studi
use
transient
overexpress
merscov
accessori
protein
show
merscov
accessori
protein
inhibit
type
ifn
induct
nfkappab
signal
pathway
merscov
doublestrand
rna
dsrna
bind
protein
potenti
act
antagonist
antivir
activ
ifn
via
inhibit
interferon
product
promot
activ
activ
isr
promot
element
signal
pathway
merscov
hand
enzym
famili
phosphodiesteras
pde
activ
even
though
merscov
detect
primarili
nucleu
infect
transfect
cell
express
level
cytoplasm
merscov
still
suffici
inhibit
activ
rnase
l
interferoninduc
potent
antivir
activ
merscov
first
identifi
rnase
l
antagonist
express
human
bat
coronaviru
provid
possibl
merscov
mechan
evas
innat
immun
inhibit
type
ifn
signal
pathway
merscov
replicas
protein
includ
also
shown
interfer
innat
immun
respons
signal
pathway
differ
mechan
evid
merscov
develop
variou
mechan
evad
host
immun
system
median
age
person
laboratoryconfirm
merscov
infect
year
rang
year
patient
male
median
time
ill
onset
hospit
approxim
four
day
result
median
length
stay
day
current
among
patient
morbid
rate
approxim
median
time
onset
symptom
death
day
chest
radiographi
comput
tomographi
find
gener
consist
viral
pneumon
acut
respiratori
distress
syndrom
laboratori
find
includ
lymphopenia
thrombocytopenia
elev
lactat
dehydrogenas
level
case
consumpt
coagulopathi
elev
creatinin
lactat
dehydrogenas
liver
enzym
clinic
spectrum
merscov
infect
rang
asymptomat
infect
rapidli
progress
acut
respiratori
distress
syndrom
septic
shock
multiorgan
failur
death
see
review
clinic
spectrum
initi
symptom
often
nonspecif
patient
report
gener
malais
includ
low
grade
fever
chill
headach
nonproduct
cough
dyspnea
myalgia
symptom
includ
sore
throat
similar
sarscov
merscov
patient
also
present
gastrointestin
symptom
anorexia
nausea
vomit
abdomin
pain
diarrhea
atyp
present
includ
mild
respiratori
ill
without
fever
diarrheal
ill
preced
develop
pneumonia
document
adult
symptomat
patient
requir
intens
care
unit
icu
treatment
patient
often
show
sign
improv
typic
requir
mechan
ventil
within
first
week
renal
replac
therapi
requir
critic
ill
patient
higherend
estim
possibl
due
overestim
result
hospitalacquir
infect
patient
preexist
renal
diseas
merscov
link
sever
diseas
older
peopl
peopl
weaken
immun
system
chronic
diseas
cancer
chronic
lung
diseas
diabet
major
patient
hospit
merscov
infect
chronic
comorbid
obes
diabet
hypertens
cardiovascular
diseas
endstag
renal
diseas
fact
patient
test
posit
merscov
least
one
comorbid
diseas
fatal
case
like
underli
condit
among
fatal
case
vs
among
recov
asymptomat
case
interestingli
merscov
case
report
mainli
adult
children
rare
affect
even
recent
case
studi
merscov
infect
child
newli
diagnos
infantil
nephrot
syndrom
show
complic
result
sever
respiratori
symptom
multiorgan
dysfunct
death
anoth
studi
pediatr
case
test
posit
merscov
two
symptomat
patient
syndrom
cystic
fibrosi
respect
indic
sever
diseas
could
potenti
occur
children
seriou
underli
condit
even
report
pediatr
case
data
infect
children
remain
scarc
make
difficult
ascertain
whether
merscov
realli
predominantli
adult
diseas
whether
often
present
differ
children
simultan
infect
respiratori
tract
least
two
virus
common
hospit
patient
although
clear
whether
infect
less
sever
singl
viru
infect
mix
clinic
featur
commonli
observ
make
clinic
diagnosi
unreli
sever
limit
epidemiolog
studi
etiolog
agent
similar
respiratori
virus
merscov
found
combin
second
respiratori
viru
influenza
viru
respiratori
syncyti
viru
human
parainfluenza
viru
human
metapneumoviru
merscov
infect
patient
requir
mechan
ventil
also
exhibit
similar
coinfect
profil
nosocomi
bacteri
infect
includ
klebsiella
pneumonia
staphylococcu
aureu
acinetobact
speci
candida
speci
preced
concurr
viral
respiratori
tract
infect
predispos
host
secondari
coinfect
microorgan
throughout
airway
mechan
virus
promot
superinfect
divers
replet
yet
much
known
merscov
damag
airway
dysregul
lung
barrier
function
turn
support
adher
invas
pathogen
normal
steril
site
within
respiratori
tract
neuromuscular
complic
rare
mer
treatment
could
simpli
underdiagnos
previous
first
case
sever
neurolog
syndrom
character
vari
degre
disturb
conscious
ataxia
focal
motor
deficit
bilater
hyperintens
lesion
report
retrospect
studi
patient
icu
anoth
subsequ
small
retrospect
studi
saudi
arabia
report
mer
patient
develop
confus
experienc
kind
seizur
date
case
central
nervou
system
involv
includ
one
case
intracerebr
haemorrhag
result
thrombocytopenia
dissemin
intravascular
coagul
platelet
dysfunct
one
case
critic
ill
polyneuropathi
four
case
includ
bickerstaff
enceph
overlap
guillainbarr
syndrom
intensivecareunitacquir
weak
toxic
infecti
neuropathi
report
neurolog
complic
latter
studi
appear
concomitantli
respiratori
symptom
delay
week
merscov
detect
respiratori
tract
secret
tracheal
secret
bronchoalveolar
lavag
specimen
contain
higher
viral
load
nasopharyng
swab
viru
also
detect
fece
serum
urin
viru
excret
peak
approxim
day
onset
symptom
viabl
virus
shed
respiratori
secret
day
clinic
fulli
recov
patient
healthcar
set
merscov
isol
environment
object
bed
sheet
bedrail
iv
fluid
hanger
xray
devic
anoth
studi
also
report
merscov
could
surviv
longer
two
day
c
rel
humid
confirm
risk
contact
fomit
transmiss
healthcar
set
viral
rna
hand
detect
five
day
environment
surfac
follow
last
posit
pcr
patient
respiratori
sampl
rna
detect
sampl
anteroom
medic
devic
airventil
equip
necessarili
indic
viabl
viru
specif
reliabl
antivir
drug
vaccin
approv
clinic
use
merscov
infect
rapid
diagnost
test
requir
manag
outbreak
viru
first
probe
primer
set
merscov
detect
realtim
rtpcr
develop
shortli
initi
report
diseas
earli
diagnost
tool
includ
viru
cultur
vero
cell
isol
identif
virus
cell
cultur
slow
special
insensit
method
laboratori
detect
confirm
merscov
infect
broadli
includ
molecular
detect
merscov
rna
ii
merscov
antigen
detect
iii
assay
identifi
humor
respons
prior
merscov
infect
among
human
tabl
assay
use
vari
degre
success
term
specif
sensit
etc
current
accord
case
definit
posit
realtim
rtpcr
assay
target
least
two
differ
genom
region
use
confirm
merscov
infect
http
wwwwhointcsr
diseasecoronavirusinfectionscasedefinitionenindexhtml
differ
assay
probe
primer
set
use
target
upstream
e
gene
show
highest
sensit
remain
wide
use
target
merscov
detect
addit
singl
posit
assay
result
confirm
gene
sequenc
also
consid
posit
merscov
infect
stumbl
block
though
fact
compar
realtim
pcr
convent
rtpcr
typic
gener
lower
qualiti
sequencereadi
templat
therebi
limit
use
convent
rtpcr
singl
positivesequenc
assay
molecular
test
detect
nucleic
acid
deriv
merscov
clinic
respiratori
serum
stool
specimen
howev
major
obstacl
convent
nucleic
acidbas
test
requir
special
molecular
techniqu
equip
therefor
appropri
pointofcar
test
bedsid
diagnosi
reason
effect
diagnosi
treatment
merscov
infect
necessari
develop
altern
method
adapt
rapid
reliabl
clinic
detect
merscov
antigen
appropri
test
would
assay
detect
viral
antigen
antibodi
infect
host
immunofluoresc
assay
highli
sensit
antigen
base
detect
cross
reactiv
seen
convalesc
sar
patient
sera
assay
use
whole
viru
portion
spike
protein
ppnt
assay
highli
sensit
sensit
mnt
test
lack
mer
neutral
activ
indic
high
specif
assay
cross
reactiv
seen
sarscov
assay
design
two
differ
gene
use
codon
optim
spike
gene
hivmer
pseudoparticl
gener
mnt
test
highli
sensit
less
ppnt
assay
highli
specif
sarscov
antigen
detect
compar
merscov
test
design
detect
igg
antibodi
gener
use
rbd
subunit
spike
gene
protein
microarray
highli
sensit
assay
use
protein
microarray
technolog
detect
igg
igm
antibodi
cross
reactiv
seen
sera
patient
expos
four
common
hcov
assay
design
use
receptorbind
subunit
spike
protein
mer
sar
antigen
one
pot
rtlamp
laboratori
anim
speci
often
use
model
human
diseas
progress
also
need
studi
evalu
novel
therapi
emerg
virus
studi
shown
rabbit
ferret
syrian
hamster
wildtyp
mice
suitabl
model
merscov
infect
recent
four
transgen
mous
model
merscov
infect
develop
first
modifi
adenoviru
express
human
introduc
intranas
mice
result
express
cell
lung
nativ
express
model
mice
show
transient
human
express
mild
lung
diseas
concern
model
cell
constitut
express
infect
role
broader
infect
cell
type
may
chang
pathogenesi
second
model
transgen
mous
produc
express
system
model
merscov
infect
lead
high
level
viral
rna
inflamm
lung
unfortun
signific
inflamm
viral
rna
also
detect
brain
infect
mice
repres
nonphysiolog
express
pattern
third
model
novel
transgen
human
mous
model
gener
replac
mous
code
sequenc
encod
ensur
correct
physiolog
express
mice
model
show
lung
patholog
consist
radiograph
find
interstiti
pneumonia
signific
lung
diseas
seen
human
infect
merscov
suggest
mous
model
recapitul
patholog
sequela
seen
merscov
infect
human
importantli
unlik
seen
mous
model
merscov
infect
viru
replic
patholog
mice
local
lung
inflamm
develop
brain
ensur
physiolog
accur
model
human
diseas
final
cockrel
et
al
gener
mous
model
permiss
merscov
infect
function
immun
function
infect
mous
mouseadapt
strain
merscov
mimic
merscovinduc
respiratori
diseas
without
bystand
neurolog
diseas
nonhuman
primat
model
includ
rhesu
macaqu
common
marmoset
also
report
suitabl
anim
model
merscov
infect
even
though
speci
suscept
merscov
infect
extent
viru
replic
sever
diseas
vari
rhesu
macaqu
infect
merscov
via
intratrach
inocul
show
clinic
sign
diseas
viru
replic
histolog
lesion
neutral
antibodi
product
indic
monkey
model
suitabl
studi
merscov
infect
hand
common
marmoset
reproduc
sever
featur
merscov
infect
potenti
use
evalu
novel
therapi
human
use
vaccin
specif
antivir
drug
avail
outbreak
nonspecif
therapeut
intervent
often
introduc
prevent
sever
morbid
mortal
howev
done
effect
basic
understand
pathogenesi
diseas
requir
intervent
implement
base
observ
clinic
cours
diseas
complic
due
natur
mani
diseas
howev
often
possibl
assess
systemat
compar
differ
therapeut
approach
outbreak
similarli
case
merscov
necessari
monitor
epidem
pattern
investig
spread
infect
effici
identifi
control
prevent
possibl
epidem
merscov
infect
support
care
includ
rest
fluid
analges
use
mainli
depend
provis
organ
support
manag
complic
broadspectrum
antimicrobi
antivir
antifung
use
minim
risk
coinfect
opportunist
pathogen
interestingli
combin
treatment
ribavirin
interferon
inhibit
merscov
replic
vitro
also
shown
improv
clinic
outcom
merscovinfect
nonhuman
primat
howev
treatment
rhesu
macaqu
initi
soon
viral
challeng
h
result
reduc
diseas
sever
rhesu
macaqu
model
appear
simul
mildtomoder
human
merscov
case
make
difficult
extrapol
outcom
earli
intervent
sever
human
case
even
though
author
recommend
combin
ribavirin
therapi
consid
earli
intervent
therapi
merscov
also
need
keep
mind
due
limit
effect
therapeut
window
opportun
broad
spectrum
antivir
might
suffici
treat
sever
merscov
patient
resveratrol
shown
inhibit
variou
human
virus
vivo
vitro
includ
influenza
viru
epsteinbarr
viru
herp
simplex
viru
respiratori
syncyti
viru
varicella
zoster
viru
enteroviru
human
metapneumoviru
human
rhinoviru
polyomaviru
cytomegaloviru
review
antivir
effect
resveratrol
mainli
associ
inhibit
viral
replic
protein
synthesi
gene
express
andor
nucleic
acid
synthesi
vitro
studi
resveratrol
shown
significantli
inhibit
merscov
infect
like
due
observ
inhibit
merscov
nucleocapsid
n
protein
express
multifunct
protein
essenti
cov
replic
furthermor
resveratrol
downregul
apoptosi
induc
merscov
therebi
prolong
cellular
surviv
postinfect
although
benefici
role
resveratrol
sever
viral
diseas
well
document
advers
effect
also
report
includ
increas
viral
rna
replic
hepc
viru
infect
vitro
cell
strong
cytotox
cultur
cell
well
enhanc
hbv
transcript
replic
vitro
vivo
clearli
antivir
potenti
resveratrol
merscov
infect
need
studi
extens
base
variou
unintend
neg
effect
need
proceed
caution
recent
de
wild
et
al
report
vitro
test
lowmicromolar
concentr
alisporivir
nonimmunosuppress
cyclosporin
aanalog
inhibit
replic
four
differ
coronavirus
includ
merscov
studi
ribavirin
found
potenti
antivir
effect
alisporivir
vitro
infect
model
warrant
explor
cyclophilin
inhibitor
potenti
hostdirect
broadspectrum
inhibitor
coronaviru
replic
proteas
pro
analog
picornaviru
proteas
pro
function
import
cov
replic
cycl
thu
regard
valid
drug
target
peptidomimet
inhibitor
enteroviru
pro
inhibit
merscov
pro
merscovinfect
cell
inhibitor
show
antivir
activ
downregul
viral
protein
product
cell
well
reduc
releas
infecti
viral
particl
cultur
supernat
compound
exhibit
good
select
index
investig
inhibitor
merscov
replic
infect
also
broadspectrum
antivir
activ
drug
cov
picornavirus
laboratori
also
previous
screen
zinc
drugsnow
librari
candid
potenti
pro
activ
consensu
highthroughput
pharmacophor
model
molecular
dock
approach
molecular
dynam
use
confirm
result
obtain
structurebas
techniqu
result
highli
defin
hitlist
compound
repres
valuabl
scaffold
could
use
basi
futur
anticoronavir
inhibitor
discoveri
experi
even
potenti
antimerscov
candid
experiment
intervent
demonstr
signific
benefit
acut
ill
patient
consist
control
manner
therefor
support
manag
adapt
guidelin
develop
sarscov
thu
far
mainstay
merscov
treatment
highli
sophist
immun
evas
mechan
viral
pathogen
human
vaccin
develop
remain
major
challeng
addit
develop
safe
effect
coronaviru
vaccin
even
challeng
curtail
major
obstacl
includ
coronaviru
immun
often
wane
rapidli
individu
need
protect
includ
elderli
vaccin
may
exacerb
rather
prevent
coronaviru
lung
immunopatholog
variou
vaccin
merscov
design
one
current
test
clinic
trial
tabl
merscov
structur
protein
could
potenti
induc
neutral
antibodi
protect
respons
howev
prior
identif
major
neutral
antibodyinduc
epitop
inactiv
virus
could
use
product
firstgener
vaccin
easi
firstrespons
approach
sinc
rel
simpl
produc
whole
kill
viru
particl
mani
safeti
concern
associ
product
inactiv
vaccin
type
vaccin
must
prefer
replac
safer
effect
neutral
epitopebas
vaccin
soon
fragment
contain
neutral
epitop
identifi
current
merscov
vaccin
provid
effect
protect
anim
model
tabl
merscov
vaccin
develop
adapt
emerg
middl
east
respiratori
syndrom
mer
discoveri
mer
coronaviru
merscov
suggest
anoth
sarslik
epidem
occur
unlik
sever
acut
respiratori
syndrom
sar
epidem
rapidli
disappear
less
one
year
mer
persist
three
year
case
mer
report
worldwid
diseas
carri
worryingli
high
fatal
rate
number
seem
low
viru
remain
global
threat
due
propens
caus
sever
diseas
patient
underli
medic
condit
appar
abil
readili
spread
within
hospit
set
addit
pattern
merscov
lineag
consist
movement
infect
livestock
anim
product
epidemiolog
evid
suggest
period
introduc
human
popul
increas
risk
variou
futur
pandem
even
though
clinic
outcom
merscov
infect
well
document
comprehens
populationbas
studi
requir
determin
involv
merscov
bodi
system
addit
continu
develop
technolog
routin
accur
identifi
asymptomat
merscov
infect
shed
light
true
incid
viru
human
popul
would
appear
merscov
circul
human
popul
greater
one
year
without
detect
suggest
independ
transmiss
unknown
sourc
howev
discuss
previous
regard
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
evolutionari
aspect
mutat
rate
select
pressur
consid
understand
evolutionari
dynam
merscov
possibl
differ
molecular
clock
rate
merscov
anim
host
human
may
also
taken
account
similarli
genom
evolut
influenza
virus
merscov
might
experi
differ
evolutionari
cours
differ
host
better
understand
dynam
chain
merscov
zoonot
transmiss
clarifi
hcov
detail
manipul
merscov
genom
understand
role
merscov
viral
gene
pathogenesi
replic
subsequ
develop
merscov
vaccin
vector
need
develop
merscov
fulllength
infecti
clone
alreadi
allow
systemat
experiment
studi
role
variou
correspond
merscov
protein
lead
better
understand
role
viral
gene
infect
pathogen
manipul
viru
genom
also
provid
revers
genet
platform
could
lead
futur
develop
merscovbas
vector
vaccin
result
increas
mer
spread
world
health
organis
cdc
center
diseas
control
releas
variou
case
definit
allow
likelihood
pandem
threat
reduc
fever
pneumonia
acut
respiratori
distress
syndrom
histori
travel
arab
peninsula
symptom
use
diagnos
merscov
infect
due
increas
nosocomi
infect
health
care
worker
also
advis
awar
upper
respiratori
tract
infect
exposur
merscovposit
individu
forese
futur
import
measur
prevent
nosocomi
outbreak
includ
good
complianc
appropri
person
protect
equip
healthcar
worker
manag
patient
suspect
confirm
merscov
infect
earli
diagnosi
prompt
isol
infect
patient
improv
ventil
healthcar
facil
acknowledg
burtram
c
field
receiv
fund
nation
research
foundat
nrf
south
africa
univers
western
cape
senat
research
fund
opinion
find
conclus
recommend
express
materi
author
therefor
nrf
accept
liabil
regard
thereto
author
contribut
burtram
c
field
aasiyah
chafekar
made
equal
contribut
write
manuscript
